The APAC Opportunity: Why Clinical Trials Are Shifting East
APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development
As geopolitical uncertainties and regulatory challenges reshape the global pharmaceutical landscape, the Asia-Pacific (APAC) region has emerged as an increasingly attractive destination for clinical trials. While trials in the European Economic Area (EEA) have seen a steady decline since 2018, APAC has experienced remarkable growth largely due to the region’s work to create a landscape that supports global drug developer’s clinical trials. Recent discussions at the global Jefferies Healthcare Conference in 2024 indicated that the APAC region was a prime location for innovation and expected to continue to grow.
Download to read the full article.
Written by: BioSpace Insights Team and CMIC Group
